Stockscreener 앱 받기
4.0666
0.33%
-0.0134
전일 마감가:
$4.08
열려 있는:
$4.06
하루 거래량:
511
Relative Volume:
0.01
시가총액:
$116.48M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+10.51%
1개월 성능:
+31.61%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$4.06
$4.07
1주일 범위
$3.5474
$4.12
52주 변동 폭
$2.33
$4.12
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
명칭
Insight Molecular Diagnostics Inc
전화
949-409-7600
주소
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
IMDX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
4.07 | 116.77M | 0 | 0 | 0 | 0.00 |
|
TMO
Thermo Fisher Scientific Inc
|
531.07 | 198.56B | 43.21B | 6.58B | 6.17B | 17.28 |
|
DHR
Danaher Corp
|
208.15 | 147.61B | 24.01B | 3.41B | 4.86B | 4.7082 |
|
IDXX
Idexx Laboratories Inc
|
640.44 | 50.96B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
139.17 | 39.13B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
205.88 | 34.81B | 15.70B | 1.24B | 2.01B | 6.9036 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-28 | 개시 | Lake Street | Buy |
| 2022-05-24 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | 개시 | Stephens | Overweight |
| 2022-01-06 | 재개 | Piper Sandler | Overweight |
| 2021-03-17 | 재개 | Needham | Buy |
| 2021-01-07 | 업그레이드 | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | 개시 | BTIG Research | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | 재확인 | The Benchmark Company | Speculative Buy |
| 2020-07-01 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | 개시 | Needham | Buy |
| 2019-02-13 | 개시 | Piper Jaffray | Overweight |
| 2019-01-29 | 업그레이드 | Janney | Neutral → Buy |
| 2018-12-19 | 재개 | Lake Street | Buy |
모두보기
Insight Molecular Diagnostics Inc 주식(IMDX)의 최신 뉴스
Insight Molecular Diagnostics names Steven Tahmooressi as VP, marketing - Medical Buyer
Insight Molecular Diagnostics appoints Steven Tahmooressi as VP of Marketing - Investing.com Nigeria
Imdx welcomes new VP Marketing to prepare for commercial transplant assay launch - MarketScreener
iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch - GlobeNewswire
GraftAssureDx kit launching 2026: iMDx hires Steven Tahmooressi as VP Marketing to lead global rollout - Stock Titan
What earnings margins imply for Insight Molecular Diagnostics Inc. (7OC0) stockQuarterly Trade Review & Long-Term Growth Portfolio Plans - newser.com
Is Insight Molecular Diagnostics Inc. (7OC0) stock included in top ETFsJuly 2025 Patterns & Community Consensus Trade Alerts - newser.com
Is Insight Molecular Diagnostics Inc. (7OC0) stock dividend growth reliable - newser.com
Will Insight Molecular Diagnostics Inc. (7OC0) stock attract long term capital inflowsQuarterly Profit Report & Accurate Technical Buy Alerts - newser.com
Bullish Insight Molecular Diagnostics Insiders Rewarded As Their Investment Rises To US$4.85m - simplywall.st
Insight Molecular Diagnostics Inc.'s (NASDAQ:IMDX) large hedge funds owners must be happy as stock continues to impress, up 12% over the past week - Yahoo Finance
iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset’ with Novel Therapy and GraftAssure Monitoring - Sahm
Insight Molecular Diagnostics stock rises after transplant study publication - Investing.com
Insight Molecular Says GraftAssure Assay Helped Avoid Overtreatment in Kidney Transplant Patient - MarketScreener
IMDX's GraftAssure Assay Shows Promise in Kidney Transplant Moni - GuruFocus
GraftAssure test helps monitor kidney transplant patient during cancer therapy By Investing.com - Investing.com Nigeria
Imdx reports kidney transplant patient achieved 'immune reset' with novel therapy and GraftAssure monitoring - MarketScreener
Molecular Diagnostics Market Analysis: Trends, Opportunities, and Forecast - newstrail.com
Why Insight Molecular Diagnostics Inc. (7OC0) stock benefits from AI revolutionJuly 2025 Price Swings & Community Trade Idea Sharing Platform - newser.com
Insight Molecular Diagnostics Extends Executive Employment Agreement - TipRanks
Insight Molecular Diagnostics grants stock options to executives and amends employment agreement - Investing.com
What analysts say about Insight Molecular Diagnostics Inc 7OC0 stockContrarian Investment Ideas & Stay Invested. Stay Smart. - earlytimes.in
Lake Street Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $8 - 富途牛牛
Autoimmune Disease Diagnostics Market Size Report, 2034 - Global Market Insights Inc.
Why Insight Molecular Diagnostics Inc. (7OC0) stock fits value portfoliosQuarterly Market Review & Smart Allocation Stock Tips - newser.com
Analysts Are Bullish on Top Healthcare Stocks: Evaxion Biotech (EVAX), Azitra Inc (AZTR) - The Globe and Mail
Molecular Diagnostics in Pharmacogenomics Market to Reach USD - openPR.com
HOLX to Discontinue Fluoroscan InSight FD Soon: Will the Stock Suffer? - TradingView
Insight Molecular Diagnostics (IMDX) Highlights GraftAssur at In - GuruFocus
Analysts’ Top Healthcare Picks: CareDx (CDNA), Semler Scientific (SMLR) - The Globe and Mail
Insight Molecular Diagnostics to Showcase Leadership in - GlobeNewswire
Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando - MarketScreener
Insight Molecular Diagnostics Approves Executive Salary Increases - TipRanks
Co-Diagnostics, Inc. Signs Strategic MOU with Partner in Kingdom of Saudi Arabia to Introduce Co-Dx™ PCR Platform to Middle East - Quantisnow
North America In Vitro Diagnostics (IVD) Market Insights and Future Outlook - openPR.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Lake Street Remains a Buy on Insight Molecular Diagnostics (IMDX) - The Globe and Mail
iMDx launches 5,000-patient registry to study transplant rejection test - Investing.com
iMDx launches 5,000-patient registry to study transplant rejection test By Investing.com - Investing.com Nigeria
Insight Molecular Diagnostics (IMDX) Launches New Patient Regist - GuruFocus
IMDX Advances GraftAssureDx Clinical Trial for Transplant Rejection Test - GuruFocus
Insight Molecular Diagnostics Inc (IMDX) 재무 분석
Insight Molecular Diagnostics Inc (IMDX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.06%
자본화:
|
볼륨(24시간):